ClinicalTrials.gg
CompletedNCT04049448Updated Nov 17, 2025

Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis

A Phase 2 interventional study of ABX464 in Rheumatoid Arthritis, sponsored by Abivax S.A.. Completed at 14 sites in 4 countries. Open to participants aged 18 Years to 76 Years. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Abivax S.A. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 76 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 290 studies in Arthritis, Rheumatoid with a site in Poland — 13 open to participants now, 22 under way, 3 of them phase 3. Arthritis, Rheumatoid · Poland.

Enrollment
268th of 284
40 · median 292
Started
2019
with 11 others
Phase 2
141 of 290
6 open now
Registered
240th of 290
by date

Among the 290 studies in Arthritis, Rheumatoid with a site in Poland, this one is the 268th largest by enrollment of the 284 interventional ones that give a count, is one of 12 that started in 2019, is one of 141 in phase 2, and was the 240th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

13 of the 290 studies in Arthritis, Rheumatoid with a site in Poland are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 76 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 290 studies in Arthritis, Rheumatoid with a site in Poland, or all of them as a file.
02

Study summary

A phase 2a open-label study to evaluate the long-term safety and efficacy of ABX464 50mg as maintenance therapy in patients with moderate to severe rheumatoid arthritis.

Read the detailed description

This Phase 2a open-label study aims at investigating the long-term safety and efficacy of an oral dose of ABX464 in patients who have been previously enrolled in the ABX464-301 clinical study and who are willing to continue their treatment.

All patients will receive ABX464 given at 50mg o.d. irrespectively of their previous treatment received in the ABX464-301 study (i.e. ABX464 or Placebo).

The enrolment in this follow-up study will be based on the willingness of the subject to carry on his/her participation and also based on investigator's judgement.

Patients will be treated with ABX464 for a period of 52 weeks. If they achieve a clinical response on Week 52 (defined as DAS28-CRP ≤ 2,6 for anti-TNFα naïve patients or DAS-28-CRP ≤ 3,2 for patients previously treated by anti-TNFα), they will be eligible to continue treatment for up to 104 weeks.Patients will be followed up at week , week 2 and then, on a monthly basis the first year (up to W52), and quaterly the second year (up to W104).

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • moderate to severe Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 76 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients previously enrolled in the ABX464-301 clinical study who have completed the initial 12 weeks of treatment period;

Criteria that should be met by patients at week 52 to be eligible for 52 additional weeks of study treatment:

▪ Patients should be in clinical response. Clinical response is defined as: DAS28-CRP ≤ 2,6 for anti-TNFα naïve patients or DAS-28-CRP ≤ 3,2 for patients previously treated by anti-TNFα.

Exclusion criteria

Exclusion Criteria:

  • Any condition, which in the opinion of the investigator, could compromise the patient's safety or adherence to the study protocol
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    ABX464 50 mg

    All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks)

    Drug: ABX464

Interventions

  • DrugABX464

    All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks).

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events in the ABX464 treated Patients, categorized by severity

    Incidence of adverse events emerging during the treatment

    Time frame: through study completion (average of 104 weeks)

Secondary outcomes

  1. Proportion of patients achieving Low Disease Activity (LDA)

    Low Disease Activity (LDA) is defined as DAS28-ESR \<=3.2

    Time frame: Week 4, Week 12, Week 24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104

  2. Proportion of patients achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean remission

    The ACR/EULAR boolean-based remission is a validated criteria based on: Tender/painful Joint Count (28), Swollen Joint Count (28), C-Reactive Protein, patient global assessment of disease, All ≤ 1

    Time frame: Week 4, Week 12, Week24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104

  3. Proportion of patients achieving Simplified Disease Activity Score (SDAI) remission

    The SDAI remission is considered achieved if the SDAI score ≤ 3.3

    Time frame: Week 4, Week 12, Week 24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104

  4. Proportion of patients achieving Clinical Disease Activity (CDAI) remission

    The CDAI remission is considered achieved if the CDAI score ≤ 2.8

    Time frame: Week 4, Week 12, Week 24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104

  5. Proportion of patients achieving ACR20/50/70 response

    The categorical American College of Rheumatology 20% or 50% or 70% (ACR20/50/70) response is a validated index of rheumatoid arthritis disease activity, defined by the number of patients who achieved at least 20% or 50% or 70% improvement in the ACR response.

    Time frame: Week 4, Week 12, Week 24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104

  6. Proportion of patients achieving categorical Disease Activity Scores (DAS) (measured on 28 joints) - C-Reactive Protein (DAS28-CRP) response

    Proportion of patients achieving categorical Disease Activity Score (DAS) DAS28-C-Reactive Protein (CRP) \[DAS28-CRP\] response will be measured as moderate/good European League Against Rheumatism (EULAR) response

    Time frame: Week 4, Week 12, Week 24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104

  7. Time to onset of the Low Disease Activity (LDA) remission

    time when DAS28-ESR \<=3.2

    Time frame: up to 104 weeks

  8. Time to onset of the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean remission

    The ACR/EULAR remission is a validated criteria based on: Tender/painful Joint Count (28), Swollen Joint Count (28), C-Reactive Protein, patient global assessment of disease, All ≤ 1. Time to onset will be when this criteria will be ≤ 1

    Time frame: up to 104 weeks

07

Study locations

14 sites
  • Cliniques Universitaires Saint-Luc
    Brussels, Belgium
  • UZ Gent
    Ghent, Belgium
  • CHU de Brest - Hôpital Cavale Blanche
    Brest, France
  • CHU DE MONTPELLIER - Hôpital Lapeyronie
    Montpellier, France
  • CHR d'Orléans
    Orléans, France
  • Complex Medical Centre - Déli Klinika
    Budapest, Hungary
  • CRU Hungary Ltd.
    Miskolc, Hungary
  • CMed Rehabilitációs és Diagnosztikai Központ
    Székesfehérvár, Hungary
  • ClinicMed Daniluk, Nowak Sp. J.
    Bialystok, Poland
  • Pratia MCM
    Krakow, Poland
  • Zespół Poradni Specjalistycznych REUMED
    Lublin, Poland
  • NZOZ Lecznica MAK-MED S.C.
    Nadarzyn, Poland
  • Medyczne Centrum Hetmańska
    Poznan, Poland
  • National Institute of Geriatrics
    Warsaw, Poland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Jan 2023, 38 months.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 38 months is above that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2019
First posted
Aug 8, 2019
StartActual
Oct 25, 2019
Primary completionActual
Jan 23, 2023
CompletionActual
Jan 23, 2023
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04049448
Lead sponsor
Abivax S.A.
Responsible party
Sponsor
First posted
Aug 8, 2019
Start date
Oct 25, 2019
Primary completion
Jan 23, 2023
Completion
Jan 23, 2023
Last update
Nov 17, 2025

Study contacts

Laurence Desroys du Roure, PharmD
study chair · Abivax S.A.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABX464

Start the discussion